Clinical trials · Ohio
Glioma clinical trials in Ohio
We’re tracking 29 recruiting glioma studies with a site in Ohio — including Early Phase 1, Phase 1, Phase 1/Phase 2, Phase 2, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in Ohio
- NCT05009992RecruitingPhase 2
Drug combination for diffuse midline gliomas in children and young adults
This Phase 2 trial studies whether a combination of medicines (including ONC201/related study drugs) can better treat diffuse midline gliomas, a type of brain/spinal cord tumor that often affects the midline. You may qualify if your tumor diagnosis is confirmed and your treatment timing (before radiation, after radiation, or at recurrence) matches one of the study groups.
Columbus, OhioAges 2–39 - NCT06333899RecruitingEarly Phase 1
Lorlatinib for newly diagnosed brain tumors with ROS or ALK fusion
This trial tests if lorlatinib, a targeted pill, can shrink or slow the growth of high-grade brain tumors that have a specific ROS or ALK genetic change. It is for children and young adults who have not yet had treatment for their tumor.
Columbus, OhioAges 1–21 - NCT06964737RecruitingPhase 1
CAR T-cell therapy for recurrent brain tumors
This trial tests a new type of immunotherapy called CAR T-cells that target a protein called GARP on your tumor cells. It is for people whose high-grade glioma (a fast-growing brain tumor) has come back after previous treatment.
Columbus, OhioAges 18 years+ - NCT05839379Recruiting
Targeted therapy study for children and young adults with brain tumors
This trial studies a targeted medicine approach for high-grade glioma (a fast-growing brain tumor) and some diffuse midline tumors, including DIPG. It may help by matching treatment to tumor biology using tumor testing done before or around starting standard therapy.
Columbus, OhioAges 1–39 - NCT05843253RecruitingPhase 2
Ribociclib plus everolimus or temozolomide for certain brain tumors
This Phase 2 study tests ribociclib with either everolimus or temozolomide, depending on the specific brain tumor type. It may help slow tumor growth in children and young adults whose tumor has specific genetic changes and who have had recent standard radiation therapy.
Columbus, OhioAges 1–39 - NCT04166409RecruitingPhase 3
Selumetinib versus chemo for low-grade brain tumor in children
This trial studies whether the targeted drug selumetinib works better than standard chemotherapy (carboplatin and vincristine) for children and young adults with a specific type of low-grade glioma (grade 1 or 2). It may help shrink tumors and slow growth while comparing side effects between the two treatment approaches.
Akron, OhioAges 2–21 - NCT05278208RecruitingPhase 1/Phase 2
Lutathera for high-grade brain tumors that returned or got worse
This trial tests if Lutathera, a radioactive drug that targets certain tumors, can help children and young adults with high-grade brain tumors or meningiomas that have come back or are growing. It aims to see if the treatment is safe and works.
Cincinnati, OhioAges 4–39 - NCT03101813Recruiting
Share DIPG/DMG tumor information for an international registry
This trial builds an international registry (a secure collection of patient records) for people who have been diagnosed with DIPG/DMG, including children and adults. Sharing information can help researchers better understand these tumors and plan future studies.
Cincinnati, OhioAges Any age - NCT06161974RecruitingPhase 2
Olutasidenib and temozolomide for IDH1-mutant high-grade glioma
This trial tests a combination of two oral medications, olutasidenib and temozolomide, for people with a specific type of aggressive brain tumor (high-grade glioma) that has an IDH1 mutation. The goal is to see if this combination can help control the tumor after standard treatment like radiation.
Columbus, OhioAges 12–39 - NCT07680439RecruitingPhase 2
CAR T cell therapy study for children with DIPG brain tumor
This trial tests a new CAR T cell therapy (BCB-276) for children and young adults with a type of brain tumor called DIPG. The therapy uses your own immune cells that are specially trained to attack the cancer.
Columbus, OhioAges 1–26 - NCT06838676RecruitingPhase 2
ACT001 for DIPG and H3K27-altered high-grade gliomas
This trial tests a drug called ACT001 for people with diffuse intrinsic pontine glioma (DIPG) or certain high-grade gliomas that have a specific genetic change (H3K27-altered). It includes two groups: one for newly diagnosed DIPG after radiation, and another for progressive or recurrent disease.
Cincinnati, OhioAges 1–39 - NCT05099003RecruitingPhase 1/Phase 2
Selinexor plus radiation for newly diagnosed brain tumors
This trial studies whether adding selinexor to standard radiation can improve outcomes for children and young teens with certain newly diagnosed high-grade brain tumors (including DIPG). It’s designed for specific tumor types and genetic markers, and people must be able to start treatment soon after diagnosis.
Akron, OhioAges 1–21 - NCT04655404RecruitingEarly Phase 1
Larotrectinib for children with newly diagnosed glioma with NTRK fusion
This trial tests larotrectinib, a targeted cancer medicine, in children and teens with newly diagnosed high-grade brain glioma that has an NTRK fusion. It may help shrink or control tumors by targeting a specific genetic change in the cancer.
Columbus, OhioAges Up to 21 years - NCT04870944RecruitingPhase 1/Phase 2
CBL0137 for children with advanced solid or brain tumors
This early-phase study tests CBL0137 in children and teens whose cancer has come back or is not responding to treatment. It is also for some specific hard-to-treat brain tumors, to see if the drug is safe and can work against the cancer.
Cincinnati, OhioAges 1–21 - NCT05538130RecruitingPhase 1
Study medicine for BRAF-mutated advanced solid tumors
This Phase 1 trial studies how PF-07799544 works and what dose is safest in people with advanced cancer that has a specific genetic change called BRAF V600. You may receive it alone or with another treatment, depending on the tumor group, to see if it can treat the cancer.
Cleveland, OhioAges 16 years+ - NCT05303519RecruitingPhase 3
Safusidenib for IDH1-mutant glioma after main treatment
This Phase 3 trial tests safusidenib, a targeted medicine, to help stop or slow the return of certain brain tumors with an IDH1 mutation. It focuses on people after initial treatment (surgery and/or radiation and temozolomide), aiming to improve outcomes during maintenance therapy.
Cleveland, OhioAges 18 years+ - NCT05096481RecruitingPhase 2
Vaccine trial for children with certain brain tumors
This Phase 2 study tests a vaccine made to target CMV (a virus) in order to treat children with medulloblastoma or newly diagnosed high-grade glioma/DIPG. If you’re eligible, you’d receive the study vaccine and the team would closely watch how well it’s tolerated and how your cancer responds.
Cincinnati, OhioAges 3–39 - NCT05565118RecruitingPhase 1
Brain activity study during surgery for high-grade glioma
This early-stage study measures electrical brain activity during brain tumor surgery to see if it can predict tumor return or progression. You may be offered the additional measurements while your surgeon removes a suspected or known high-grade glioma.
Cleveland, OhioAges 18 years+ - NCT05580562RecruitingPhase 3
ONC201 for newly diagnosed H3 K27M brain tumor after radiation
This study tests whether ONC201 (also called ONC201) can improve outcomes for people with a newly diagnosed H3 K27M–mutant diffuse brain tumor after they finish radiation. It looks for safety and whether treatment can help control the tumor.
Cincinnati, OhioAges Any age - NCT06810544RecruitingPhase 1/Phase 2
Study of TNG456 for tumors with MTAP loss
This trial tests a new drug called TNG456, alone or with another drug (abemaciclib), for people whose tumors have lost the MTAP gene. It aims to see if the combination can shrink tumors or slow their growth.
Columbus, OhioAges 18 years+ - NCT06860594RecruitingPhase 1
Triapine plus radiation for recurrent brain tumors
This trial tests whether adding an experimental drug called triapine to a second round of radiation therapy can help treat brain tumors that have come back after initial treatment. It may be a good option for people with recurrent glioblastoma or astrocytoma who meet safety criteria.
Columbus, OhioAges 18 years+ - NCT07346144RecruitingPhase 1/Phase 2
Gene therapy study for high-grade glioma
This trial tests a new gene therapy given directly into the brain tumor. It's for people with high-grade glioma, either newly diagnosed or after one recurrence, to see if it can help control the tumor.
Columbus, OhioAges 18–70 - NCT03340506RecruitingPhase 4
Follow-on treatment study for dabrafenib and trametinib
This study lets people who finished a prior dabrafenib/trametinib trial (sponsored by Novartis or former GSK) continue those medicines if the study doctor thinks it will help. It mainly focuses on ongoing treatment benefit rather than testing a new drug.
Columbus, OhioAges 18–100 - NCT03122197RecruitingEarly Phase 1
Letrozole for recurrent high-grade brain tumors
This early-phase study tests letrozole, a hormone-blocking medicine, in adults with recurrent high-grade gliomas. The goal is to see if it can help control the tumor and is safe enough to study further.
Cincinnati, OhioAges 18 years+
Glioma trials by city in Ohio
Where these studies are running in Ohio
Institutions with a site for the recruiting glioma studies listed above.
- Cincinnati Children's Hospital Medical Center · 13 studies
- Nationwide Children's Hospital · 12 studies
- The Ohio State University Wexner Medical Center · 5 studies
- Cleveland Clinic · 4 studies
- Children's Hospital Medical Center of Akron · 2 studies
- Dayton Children's Hospital · 2 studies
- Rainbow Babies and Children's Hospital · 2 studies
- ProMedica Toledo Hospital
What taking part in a glioma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Glioma trials in other states
Common questions
- Are there glioma clinical trials in Ohio?
- Yes. We're currently tracking 29 recruiting glioma studies with a site in Ohio, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a glioma study in Ohio?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Ohio to take part?
- Not necessarily. These studies have a site in Ohio, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a glioma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New glioma studies open in Ohio regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.